New research reveals that Alzheimer's genetic mutations can damage nerves controlling muscle movement independently of brain damage, suggesting movement problems may signal early disease.
By Adam Makins·
Scientists at the University of Central Florida have upended conventional thinking about Alzheimer’s disease by discovering that genetic mutations associated with the condition can wreak havoc on peripheral nerves and muscles without ever touching the brain or spinal cord.
This finding challenges everything we thought we knew about how Alzheimer’s develops. The research team, led by Professor James Hickman and Research Professor Xiufang “Nadine” Guo, demonstrated that motor neurons carrying familial Alzheimer’s mutations can disrupt the connections responsible for muscle control, even in laboratory systems completely absent of brain tissue. The implications are staggering: movement difficulties like changes in gait, balance, and coordination could represent early warning signs of the disease, appearing years before memory loss becomes noticeable.
For decades, researchers treated Alzheimer’s as essentially a brain disease. Memory problems, confusion, and cognitive decline dominated the clinical picture. Yet doctors have long observed something puzzling: some patients develop physical symptoms long before cognitive deficits emerge. This disconnect prompted a critical question: Are these movement problems simply collateral damage from brain degeneration, or is something else happening?
The UCF team focused on familial Alzheimer’s, a rare inherited form that typically strikes between ages 40 and 65. Using innovative “human-on-a-chip” technology developed by the company Hesperos, they created miniature models of the neuromuscular junction, the precise point where motor neurons communicate with muscle cells.
The experimental design was deliberately stripped down. No brain. No spinal cord. Just motor neurons carrying Alzheimer’s mutations paired with healthy muscle tissue. The results were unambiguous: the mutated neurons disrupted normal communication with the muscles, causing measurable deficits in signal transmission and muscle endurance.
“This is the first time it’s been demonstrated that deficits in the peripheral nervous system can arise directly from these mutations,” Hickman stated. “It means drugs that target the brain may not fix problems in the rest of the body.”
The discovery opens fascinating possibilities for early disease detection. If motor dysfunction truly precedes memory loss in Alzheimer’s patients, physicians might eventually screen for the disease using walking tests, coordination assessments, or nerve-to-muscle activity measurements long before cognitive symptoms manifest.
But there’s a darker implication too. Current Alzheimer’s therapies focus almost exclusively on brain-based processes. If the disease simultaneously damages peripheral nerves, medications designed to protect cognitive function might leave half the problem untreated. Patients could lose physical independence even as their minds remain sharper longer, a grim trade-off few would welcome.
Guo emphasized an additional benefit of preserving motor function: regular physical activity supports cognitive well-being. Protecting movement capacity might inadvertently protect brain health itself, creating a virtuous cycle that brain-only treatments could never achieve.
None of this would have been possible without human-on-a-chip technology, a revolutionary approach that cultures different human cell types in controlled microenvironments. Unlike traditional cell culture, which isolates individual cell types, or animal models, which don’t always reflect human disease accurately, these systems recreate actual tissue interactions in miniature form.
The platform allowed researchers to observe disease mechanisms with unprecedented precision while avoiding the ethical concerns surrounding animal testing. For Hickman, this represents the culmination of three decades developing more realistic laboratory models of disease.
“These systems let us study disease in a way that’s closer to what actually happens in the human body, and that’s what we need to develop better treatments,” he explained.
The research suggests a paradigm shift in how we approach neurodegenerative diseases. Rather than treating Alzheimer’s as a monolithic brain disorder, future investigations might examine how mutations simultaneously affect multiple organ systems. Treatment strategies could expand beyond neuroprotection to include therapies that safeguard both cognitive and motor function.
Of course, important questions remain unanswered. The experiments used familial Alzheimer’s mutations, which account for only a small percentage of cases. Whether these findings apply to the more common sporadic form remains unclear. Additional research will determine if the laboratory observations translate to actual disease progression in patients.
But the fundamental insight stands: we’ve been looking for Alzheimer’s in the wrong place, or at least an incomplete place. If movement changes truly herald the disease’s arrival, we’re not just gaining a new diagnostic tool, we’re potentially gaining years to intervene before memory and identity slip away.
Materials provided by University of Central Florida. Original written by Emily Dougherty.
